OPKO Health, Inc. Derivative Asset, Fair Value, Gross Asset
OPKO Health, Inc. (OPK) had Derivative Asset, Fair Value, Gross Asset of $96.00 thousand as of 2021-03-31, per its 10-Q filed 2021-04-28.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeAsset · last filed 2021-04-28
- 2021-03-31: Derivative Asset, Fair Value, Gross Asset $96.00K.
- 2020-12-31: Derivative Asset, Fair Value, Gross Asset $74.00K.
- 2020-09-30: Derivative Asset, Fair Value, Gross Asset $38.00K.
- 2020-06-30: Derivative Asset, Fair Value, Gross Asset $51.00K.
| Period end | Derivative Asset, Fair Value, Gross Asset |
|---|---|
| 2021-03-31 | $96.00K 10-Q · filed 2021-04-28 |
| 2020-12-31 | $74.00K 10-Q · filed 2021-04-28 |
| 2020-09-30 | $38.00K 10-Q · filed 2020-10-29 |
| 2020-06-30 | $51.00K 10-Q · filed 2020-07-31 |
| 2020-03-31 | $58.00K 10-Q · filed 2020-05-06 |
| 2019-12-31 | $120.00K 10-K · filed 2021-02-18 |
| 2019-09-30 | $120.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $488.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $880.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $855.00K 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |